← Eichor
Study identifier: NCT04513028 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Condition: Melanoma Stage III · Melanoma Stage IV  ·  Sponsor: Kelly McMasters

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.

This description comes directly from the study's public registry record.

Talk to the study team

Matthew Woeste, MD  ·  502-852-0325  ·  matthew.woeste@louisville.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of LouisvilleLouisville, Kentucky, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04513028